Literature DB >> 25880439

A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.

Mahadeo A Sukhai1,2, Kenneth J Craddock1,2, Mariam Thomas1,2, Aaron R Hansen3,2, Tong Zhang1,2, Lillian Siu3,2, Philippe Bedard3,2, Tracy L Stockley1,4,2, Suzanne Kamel-Reid1,4,2.   

Abstract

PURPOSE: Interpretation systems for clinical laboratory reporting of genetic variants for inherited conditions have been widely published. By contrast, there are no existing systems for interpretation and classification of somatic variants found from molecular testing of cancer.
METHODS: We designed an assessment protocol and classification system for somatic variants identified through next-generation sequencing molecular profiling of tumor-derived samples and applied these to a pilot dataset of somatic variants found by next-generation sequencing profiling of 158 tumor samples derived from advanced cancer patients examined at the Princess Margaret Cancer Centre.
RESULTS: We present a classification system to interpret the significance of genetic variants in molecular analysis of cancer, including the following key factors: (i) known or predicted pathogenicity of the variant; (ii) primary site and tumor histology in which the variant is found; (iii) recurrence of the variant; and (iv) evidence of clinical actionability. We used these factors to develop a five-category somatic variant classification for simplified reporting of variant interpretations to treating oncologists.
CONCLUSION: Our somatic variant classification can be of practical value to other clinical molecular laboratories performing cancer genetic profiling by promoting consistent reporting of somatic variants and permitting harmonization of variant data among laboratories and clinical studies.

Entities:  

Mesh:

Year:  2015        PMID: 25880439     DOI: 10.1038/gim.2015.47

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  39 in total

1.  GRADE guidelines: 2. Framing the question and deciding on important outcomes.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; David Atkins; Jan Brozek; Gunn Vist; Philip Alderson; Paul Glasziou; Yngve Falck-Ytter; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-30       Impact factor: 6.437

2.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.

Authors:  Gordon H Guyatt; Andrew D Oxman; Holger J Schünemann; Peter Tugwell; Andre Knottnerus
Journal:  J Clin Epidemiol       Date:  2010-12-24       Impact factor: 6.437

3.  A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes.

Authors:  J M Eggington; K R Bowles; K Moyes; S Manley; L Esterling; S Sizemore; E Rosenthal; A Theisen; J Saam; C Arnell; D Pruss; J Bennett; L A Burbidge; B Roa; R J Wenstrup
Journal:  Clin Genet       Date:  2013-12-20       Impact factor: 4.438

4.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

5.  Evolution and functional impact of rare coding variation from deep sequencing of human exomes.

Authors:  Jacob A Tennessen; Abigail W Bigham; Timothy D O'Connor; Wenqing Fu; Eimear E Kenny; Simon Gravel; Sean McGee; Ron Do; Xiaoming Liu; Goo Jun; Hyun Min Kang; Daniel Jordan; Suzanne M Leal; Stacey Gabriel; Mark J Rieder; Goncalo Abecasis; David Altshuler; Deborah A Nickerson; Eric Boerwinkle; Shamil Sunyaev; Carlos D Bustamante; Michael J Bamshad; Joshua M Akey
Journal:  Science       Date:  2012-05-17       Impact factor: 47.728

6.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

7.  Incidental findings in clinical genomics: a clarification.

Authors: 
Journal:  Genet Med       Date:  2013-07-04       Impact factor: 8.822

8.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Authors: 
Journal:  Genet Med       Date:  2013-02-21       Impact factor: 8.822

10.  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

View more
  34 in total

Review 1.  The current state of clinical interpretation of sequence variants.

Authors:  Derick C Hoskinson; Adrian M Dubuc; Heather Mason-Suares
Journal:  Curr Opin Genet Dev       Date:  2017-01-31       Impact factor: 5.578

Review 2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

3.  Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.

Authors:  T Spence; N Stickle; C Yu; H Chow; H Feilotter; B Lo; E McCready; B Sadikovic; L L Siu; P L Bedard; T L Stockley
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

Review 4.  The evidence framework for precision cancer medicine.

Authors:  Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2017-12-19       Impact factor: 66.675

5.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

Review 6.  Defining actionable mutations for oncology therapeutic development.

Authors:  T Hedley Carr; Robert McEwen; Brian Dougherty; Justin H Johnson; Jonathan R Dry; Zhongwu Lai; Zara Ghazoui; Naomi M Laing; Darren R Hodgson; Francisco Cruzalegui; Simon J Hollingsworth; J Carl Barrett
Journal:  Nat Rev Cancer       Date:  2016-04-26       Impact factor: 60.716

7.  Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1).

Authors:  Yoichi Naito; Hiroyuki Aburatani; Toraji Amano; Eishi Baba; Toru Furukawa; Tetsu Hayashida; Eiso Hiyama; Sadakatsu Ikeda; Masashi Kanai; Motohiro Kato; Ichiro Kinoshita; Naomi Kiyota; Takashi Kohno; Shinji Kohsaka; Keigo Komine; Itaru Matsumura; Yuji Miura; Yoshiaki Nakamura; Atsushi Natsume; Kazuto Nishio; Katsutoshi Oda; Naoyuki Oda; Natsuko Okita; Kumiko Oseto; Kuniko Sunami; Hideaki Takahashi; Masayuki Takeda; Shimon Tashiro; Shinichi Toyooka; Hideki Ueno; Shinichi Yachida; Takayuki Yoshino; Katsuya Tsuchihara
Journal:  Int J Clin Oncol       Date:  2020-11-29       Impact factor: 3.402

8.  The Somatic Curation and Interpretation Across Laboratories (SOCIAL) project-current state of solid-tumour variant interpretation for molecular pathology in Canada.

Authors:  T Spence; M A Sukhai; S Kamel-Reid; T L Stockley
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

9.  Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Authors:  Pam K Mangat; Susan Halabi; Suanna S Bruinooge; Elizabeth Garrett-Mayer; Ajjai Alva; Katherine A Janeway; Philip J Stella; Emile Voest; Kathleen J Yost; Jane Perlmutter; Navin Pinto; Edward S Kim; Richard L Schilsky
Journal:  JCO Precis Oncol       Date:  2018-07-11

Review 10.  Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.

Authors:  Dara S Ross; Fresia Pareja
Journal:  Surg Pathol Clin       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.